A recent study suggests that there is not much evidence that most new cancer drugs approved in Europe in recent years can help patients live longer or improve their quality of life. Out of 48 drugs approved by European Medicines Agency for 68 different uses between 2009-2013, only 35% had evidence that the drugs were better at helping patients live longer compared to dummy pills or alternative treatments. The survival benefit ranged about 1 to 6 months, and half the time was no more than 2.7 months. Around half of all new drugs coming on the European Union market, patients and physicians will not know whether the drugs offer survival or quality of life benefits over existing treatment options, or in some cases over no treatment. It also means that where survival benefits have been presented, they may not be worth the risk of side effects or additional toxicity for some patients.